Cancer Drugs Fund Delists Lung Cancer Therapy
The Cancer Drugs Fund has taken the decision to delist the lung cancer drug Pemetrexed from 21st July this year.
Patients will now no longer be able to access the drug in the following two indications: as maintenance therapy after first line treatment with the combination of Cisplatin and Pemetrexed, and for second line treatment, for patients with non-squamous non-small cell lung cancer.
Dr Jesme Fox, Medical Director for Roy Castle Lung Cancer Foundation, said “We are extremely disappointed that from 21st July this year, patients will no longer be able to access Pemetrexed from the Cancer Drugs Fund.
“It is estimated that over 500 patients a year, in England, have received pemetrexed in these two indications.
“Roy Castle Lung Cancer Foundation will be writing to the Chair of the Cancer Drugs Fund, to ask why an appeal to re-consider the status of the drug, which was upheld by the NHS England Programme Board in March, has now been ignored by the CDF panel.”
We understand that Lilly, the pharmaceutical company who manufacture Pemetrexed, are currently considering their position in relation to the decision.